Clostridium difficile colitis
MONDO:0000705A bacterial infection of the colon secondary to infection with Clostridium difficile bacteria. This infection generally results from the loss of normal gut flora secondary to recent antibiotic use, and manifests as copious watery stools, with associated abdominal pain and myalgia. C. difficile is the most common cause of pseudomembranous colitis, and can progress to toxic megacolon if left untreated.
Also known as: C. diff colitis, C. diff infection, Clostridioides difficile caused colitis (disease), Clostridioides difficile colitis (disease), Clostridium difficile infection, pseudomembranous colitis
121 clinical trials for this condition and its sub-types, 69 tagged with Clostridium difficile colitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a probiotic shield kids from antibiotic side effects?
Disease control CompletedThis study tests whether giving a probiotic (Saccharomyces boulardii) along with a common antibiotic can protect the gut bacteria of children aged 4 to 12 being treated for ear or sinus infections. The goal is to see if it reduces antibiotic-associated diarrhea and limits the spr…
Phase 4 • Sponsor: Eskisehir Osmangazi University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New bacteria slurry takes on poop transplants for stubborn gut infection
Disease control CompletedThis study tests two treatments for people with repeat C. diff infections: a lab-made bacteria mix called MTC01 and a fecal transplant (FMT) from a healthy donor. Both are given during a colonoscopy. The goal is to see which is safer and better at stopping the infection from comi…
Phase 1 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Poop pills could protect gut after colon surgery – early trial begins
Disease control CompletedThis early-stage trial is testing whether a pill made from freeze-dried healthy donor stool (MTP-101P) is safe and can restore good bacteria in people having part of their colon removed. Forty adults aged 18-75 with colon polyps, early-stage cancer, or diverticulitis will take th…
Phase 1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Washing therapy dogs may keep hospital germs away from kids
Disease control CompletedThis study tested whether cleaning therapy dogs with a special disinfectant (chlorhexidine) before hospital visits could reduce the spread of harmful germs to children. The trial involved 45 children aged 3 to 17 who interacted with therapy dogs. Researchers checked if the cleani…
Phase 4 • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New way to deliver c. diff treatment: through a colonoscopy
Disease control CompletedThis study tested a treatment called RBX2660 (REBYOTA) for people with recurrent Clostridioides difficile infection. The treatment is made from healthy human stool bacteria and was given during a colonoscopy. The goal was to see if this delivery method is safe and works well. For…
Phase 3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gut bacteria capsules take on superbugs in antibiotic patients
Disease control CompletedThis study tested whether taking capsules containing healthy gut bacteria could help clear drug-resistant germs (including C. difficile) from the intestines of 42 hospitalized adults who needed at least 7 days of antibiotics. Participants received either the bacteria capsules or …
Phase 1/2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New antibiotic CRS3123 takes on c. diff in early trial
Disease control CompletedThis phase 2 study tested an experimental antibiotic called CRS3123 against the standard treatment vancomycin for Clostridioides difficile infection (C. diff). 43 adults with a first episode or first recurrence of C. diff took either CRS3123 or vancomycin for 10 days. The main go…
Phase 2 • Sponsor: Crestone, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Poop pills? fecal transplants show promise for gut infections
Disease control CompletedThis study tested fecal microbiota transplant (FMT) in 24 adults with recurrent Clostridium difficile infection (C. diff) that didn't get better with standard antibiotics. FMT involves placing healthy donor stool into the patient's colon to restore good bacteria. The goal was to …
Phase 4 • Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise against deadly gut infection
Disease control CompletedThis study tested whether adding the drug bezlotoxumab to standard treatment could prevent serious outcomes in people with a severe C. diff infection. Researchers used a special score to identify 44 high-risk patients. The goal was to see if the drug reduced organ failure, infect…
Phase 2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New capsule aims to revive old antibiotic for gut infection
Disease control CompletedThis study tests a new delayed-release metronidazole capsule designed to release the drug directly in the colon, where C. diff bacteria live. 18 healthy adults will receive a single dose of either the new capsule or the standard tablet to compare how much drug reaches the colon v…
Phase 1 • Sponsor: Gateway Pharmaceutical LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Probiotic drops may stop antibiotic tummy troubles in children
Prevention CompletedThis study tests whether a probiotic supplement in oral drops can prevent diarrhea in children aged 0-12 who are taking common antibiotics like amoxicillin. One thousand children will receive either the probiotic or a placebo during their antibiotic course, and researchers will t…
Sponsor: Liaquat University of Medical & Health Sciences • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Real-world data shows REBYOTA™ may stop c. diff from coming back
Prevention CompletedThis observational study followed 145 adults who received REBYOTA™ to prevent another Clostridioides difficile infection (CDI) after completing antibiotics. Researchers collected information from medical records over 6 months to see how many people stayed infection-free. The goal…
Sponsor: Ferring Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Could a simple antibiotic taper stop c. diff relapse?
Prevention CompletedThis study tested whether extending standard vancomycin treatment for C. diff infection with a 2-week taper (lowering the dose gradually) reduces the chance of the infection returning. 263 adults who had a first episode or first recurrence of C. diff were randomly assigned to rec…
Phase 3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Stool transplant plus antibody drug shows promise against recurrent c. diff in IBD patients
Prevention CompletedThis study tested whether combining a fecal microbiota transplant (FMT) with the drug bezlotoxumab could prevent repeat Clostridium difficile infections in people with inflammatory bowel disease (IBD). Sixty-one adults with at least two prior C. diff infections were randomly assi…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Antibiotics may temporarily alter gut nerve cells, new study finds
Knowledge-focused CompletedThis study looked at how a short course of antibiotics changes the nerve and glia cells in the lower gut of 10 healthy adults. Researchers took colon tissue samples before and after antibiotic treatment to count these cells and measure gene activity. The goal was to understand if…
Phase 4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Early safety check for new c. diff drug in japanese volunteers
Knowledge-focused CompletedThis early-stage study tested a single dose of AZD5148, a potential treatment for C. difficile infection, in 16 healthy Japanese adults. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo by injection and…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Can your immune system predict a c. diff relapse?
Knowledge-focused CompletedThis study looked at how the immune system responds to Clostridium difficile infection in hospitalized patients. Researchers took blood samples every two days to measure immune markers. The goal was to find out why some patients have repeat infections. The study involved 56 parti…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Tiny study aims to improve c. diff sample collection
Knowledge-focused CompletedThis study looked at how well stool and blood samples could be collected from 7 adults with an active C. diff infection. Researchers wanted to see if the collection, shipping, and testing methods worked smoothly. Participants also filled out questionnaires about their symptoms. T…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC